Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James C Yang

Showing results (41-50 of 156) with videos related to

Pageof 16
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2002
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastasesLisa M Guirguis, James C Yang, Donald E White, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2010
Successful treatment of melanoma brain metastases with adoptive cell therapyJenny J Hong, Steven A Rosenberg, Mark E Dudley, et al.
Blood Advances|July 21, 2025
Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-upTatyana Gavrilova, Lori McIntyre, Stephanie L Goff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell TherapyKathryn M Cappell, Richard M Sherry, James C Yang, et al.
Cancer|October 5, 2002
Prospective analysis of circulating endostatin levels in patients with renal cell carcinomaAndrew L Feldman, H Richard Alexander, James C Yang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 10, 2004
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitisMichael R Robinson, Chi-Chao Chan, James C Yang, et al.
The Journal of Clinical Investigation|June 5, 2002
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cellsHelen Y Wang, Tihui Fu, Gang Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 12, 2012
Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytesKevin M Friedman, Peter A Prieto, Laura E Devillier, et al.
Folia Morphologica|February 16, 2023
Unique case of vascularization: superficial brachial artery and radial persistent median arteryMegan K Kalinowski, Jeffery M Bettag, Julian A Giakas, et al.
The New England Journal of Medicine|August 2, 2003
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerJames C Yang, Leah Haworth, Richard M Sherry, et al.
Pageof 16

Showing results (41-50 of 156) with videos related to

Sort By:
Pageof 16
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2002
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastasesLisa M Guirguis, James C Yang, Donald E White, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2010
Successful treatment of melanoma brain metastases with adoptive cell therapyJenny J Hong, Steven A Rosenberg, Mark E Dudley, et al.
Blood Advances|July 21, 2025
Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-upTatyana Gavrilova, Lori McIntyre, Stephanie L Goff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell TherapyKathryn M Cappell, Richard M Sherry, James C Yang, et al.
Cancer|October 5, 2002
Prospective analysis of circulating endostatin levels in patients with renal cell carcinomaAndrew L Feldman, H Richard Alexander, James C Yang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 10, 2004
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitisMichael R Robinson, Chi-Chao Chan, James C Yang, et al.
The Journal of Clinical Investigation|June 5, 2002
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cellsHelen Y Wang, Tihui Fu, Gang Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 12, 2012
Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytesKevin M Friedman, Peter A Prieto, Laura E Devillier, et al.
Folia Morphologica|February 16, 2023
Unique case of vascularization: superficial brachial artery and radial persistent median arteryMegan K Kalinowski, Jeffery M Bettag, Julian A Giakas, et al.
The New England Journal of Medicine|August 2, 2003
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerJames C Yang, Leah Haworth, Richard M Sherry, et al.
Pageof 16